Erick Gamelin - May 14, 2024 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Development Officer
Signature
/s/ Rasmus Holm-Jorgensen, Attorney-in-Fact
Stock symbol
ACRV
Transactions as of
May 14, 2024
Transactions value $
-$3,361
Form type
4
Date filed
5/16/2024, 06:58 PM
Previous filing
Nov 27, 2024
Next filing
Aug 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability -$3.36K -402 -2.21% $8.36 17.8K May 14, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.